naa a22 4500 510735312 CHVBK 20180411083007.0 cr unu---uuuuu 180411e20130901xx s 000 0 eng 10.1007/s11904-013-0169-5 doi (NATIONALLICENCE)springer-10.1007/s11904-013-0169-5 Update on HIV/HCV Coinfection [Elektronische Daten] [Vincent Soriano, Eugenia Vispo, Jose Fernandez-Montero, Pablo Labarga, Pablo Barreiro] Liver disease is currently one of the leading causes of hospitalization and death in HIV-positive individuals. Coinfection with the hepatitis C virus (HCV) is a major contributor to this trend. Besides hepatic damage, which is enhanced in the presence of HIV-associated immunosuppression, HCV may contribute to disease in coinfected individuals by potentiating immune activation and chronic inflammation, which ultimately account for an increased risk of cardiovascular events, kidney disease, and cancers in this population. Fortunately, hepatitis C therapeutics has entered a revolutionary era in which we hope that most patients treated with the new oral direct-acting antivirals (DAA) will be cured. However, many challenges preclude envisioning a prompt elimination of HCV from the coinfected population. Issues that should be addressed include the following: (1) rising incidence of acute hepatitis C in men who have sex with men, and expansion/recrudescence of injection drug use in some settings/regions; (2) adverse drug interactions between antiretrovirals and DAA; and (3) high cost of DAA, which may lead many to defer or fail to access appropriate therapy. Springer Science+Business Media New York, 2013 Hepatitis C nationallicence HIV nationallicence Coinfection nationallicence HIV/HCV coinfection nationallicence Sofosbuvir nationallicence Telaprevir nationallicence Boceprevir nationallicence Antiviral therapy nationallicence Soriano Vincent Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029, Madrid, Spain aut Vispo Eugenia Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029, Madrid, Spain aut Fernandez-Montero Jose Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029, Madrid, Spain aut Labarga Pablo Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029, Madrid, Spain aut Barreiro Pablo Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029, Madrid, Spain aut Current HIV/AIDS Reports Springer US; http://www.springer-ny.com 10/3(2013-09-01), 226-234 1548-3568 10:3<226 2013 10 11904 https://doi.org/10.1007/s11904-013-0169-5 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11904-013-0169-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Soriano Vincent Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029, Madrid, Spain aut NATIONALLICENCE 700 1- Vispo Eugenia Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029, Madrid, Spain aut NATIONALLICENCE 700 1- Fernandez-Montero Jose Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029, Madrid, Spain aut NATIONALLICENCE 700 1- Labarga Pablo Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029, Madrid, Spain aut NATIONALLICENCE 700 1- Barreiro Pablo Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029, Madrid, Spain aut NATIONALLICENCE 773 0- Current HIV/AIDS Reports Springer US; http://www.springer-ny.com 10/3(2013-09-01), 226-234 1548-3568 10:3<226 2013 10 11904 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer